Edison Pharmaceuticals, Inc., a Mountain View, CA-based specialty pharmaceutical company dedicated to developing treatments for children with orphan mitochondrial diseases, has closed a $20m Series F financing.
The round was led by Mitsui & Co. Global Investment, Inc., which will also take a board of directors seat.
The company intends to use the funding to advance the clinical development of EPI-743. The company has recently announced the beginning of phase 2B clinical trials in the United States in two orphan mitochondrial diseases, Leigh syndrome and Friedreich’s ataxia.
Other clinical development initiatives are underway and will be announced in Q1 2013.
Founded by Piero Barboni, MD, and led by Guy Miller, MD, PhD, Chairman, CEO, Edison Pharmaceuticals also has an office in Utrecht, The Netherlands.